Moderna (MRNA) EBIT Growth (1y) (2018 - 2026)
Powered by 
Analysis
Moderna (MRNA) EBIT Growth (1y) (2018 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 32.30% |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -520.13% |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 8.32% |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 19.82% |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 145.20% |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 10.14% |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 1,528.74% |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | -563.67% |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | Insmed | 27.67 Bn | 26.51 Bn | 358.27 Mn | 99.51% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 10.14% |
| Mar 31, 2026 | -32.19% |
| Dec 31, 2025 | 31.22% |
| Sep 30, 2025 | -271.43% |
| Jun 30, 2025 | 33.46% |
| Mar 31, 2025 | 17.06% |
| Dec 31, 2024 | -20,866.67% |
| Sep 30, 2024 | 96.52% |
| Jun 30, 2024 | 27.00% |
| Mar 31, 2024 | -245.90% |
| Dec 31, 2023 | -99.62% |
| Sep 30, 2023 | -272.56% |
| Jun 30, 2023 | -176.30% |
| Mar 31, 2023 | -108.66% |
| Dec 31, 2022 | -70.79% |
| Sep 30, 2022 | -67.23% |
| Jun 30, 2022 | -20.08% |
| Mar 31, 2022 | 233.89% |
| Dec 31, 2021 | 2,067.27% |
| Sep 30, 2021 | 1,614.04% |